Top

Published in:

01-03-2017 | Hepatic Cancer (A Singal and A Mufti, Section Editors)

Advances in Pediatric Liver Tumors

Authors: Angela D. Trobaugh-Lotrario, Allison F. O’Neill, Peng Li, Alexander Towbin, Christopher Weldon, Dolores López-Terrada, Marcio H. Malogolowkin

Published in: Current Hepatology Reports | Issue 1/2017

Abstract

Purpose of Review

Hepatoblastoma and hepatocellular carcinoma are rare pediatric tumors. We review the significant advances in hepatoblastoma and pediatric hepatocellular carcinoma prognosis and treatment.

Recent Findings

International pathologic classification and risk stratification have been extensively reviewed and redefined for hepatoblastoma via international collaborative analyses of an international hepatoblastoma database. International trials have identified patients for whom (1) no adjuvant chemotherapy is indicated, (2) neoadjuvant chemotherapy improves resectability and survival, and (3) intensified therapy improves survival (for patients with metastatic disease). Hepatocellular carcinoma studies highlight the poor prognosis for patients with nonlocalized disease emphasizing the need for future collaborative efforts exploring molecular characteristics and novel therapeutics.

Summary

Recent advances have significantly improved treatment of hepatoblastoma by implementing a consensus international pathologic classification and risk stratification and identification of higher risk biological features. Advances in pediatric hepatocellular carcinoma treatment lag behind hepatoblastoma. The Pediatric Hepatic International Tumor Trial (PHITT) will focus on decreasing long-term toxicity, improving outcomes, providing surgical guidelines, and advancing the knowledge of the biology of hepatoblastoma and hepatocellular carcinoma.

Meyers RL. Tumors of the liver in children. Surg Oncol. 2007;16(3):195–203. doi:10.1016/j.suronc.2007.07.002.CrossRefPubMed

Czauderna P, Popadiuk S, Korzon M, Stoba C, Szymik-Kantorowicz S, Sawicz-Birkowska K, et al. Multicenter retrospective analysis of various primary pediatric malignant hepatic tumors—management in a series of 47 Polish patients (1985–1995). Eur J Pediatr Surg. 2001;11(2):82–5. doi:10.1055/s-2001-14954.CrossRefPubMed

Meyers AB, Towbin AJ, Geller JI, Podberesky DJ. Hepatoblastoma imaging with gadoxetate disodium-enhanced MRI—typical, atypical, pre- and post-treatment evaluation. Pediatr Radiol. 2012;42(7):859–66. doi:10.1007/s00247-012-2366-6.CrossRefPubMed

Asayama Y, Nishie A, Ishigami K, Ushijima Y, Takayama Y, Okamoto D, et al. Heterogeneity of non-cancerous liver parenchyma on gadoxetic acid-enhanced MRI: an imaging biomarker for hepatocellular carcinoma development in chronic liver disease. Clin Radiol. 2016;71(5):432–7. doi:10.1016/j.crad.2016.01.023.CrossRefPubMed

Ikeda H, Hachitanda Y, Tanimura M, Maruyama K, Koizumi T, Tsuchida Y. Development of unfavorable hepatoblastoma in children of very low birth weight: results of a surgical and pathologic review. Cancer. 1998;82(9):1789–96.CrossRefPubMed

Gupta A, Sheridan RM, Towbin A, Geller JI, Tiao G, Bove KE. Multifocal hepatic neoplasia in 3 children with APC gene mutation. Am J Surg Pathol. 2013;37(7):1058–66. doi:10.1097/PAS.0b013e31828aeb18.CrossRefPubMed

Maas SM, Vansenne F, Kadouch DJ, Ibrahim A, Bliek J, Hopman S, et al. Phenotype, cancer risk, and surveillance in Beckwith-Wiedemann syndrome depending on molecular genetic subgroups. Am J Med Genet A. 2016;170(9):2248–60. doi:10.1002/ajmg.a.37801.CrossRefPubMed

Spector LG, Birch J. The epidemiology of hepatoblastoma. Pediatr Blood Cancer. 2012;59(5):776–9. doi:10.1002/pbc.24215.CrossRefPubMed

Tajiri H, Tanaka H, Brooks S, Takano T. Reduction of hepatocellular carcinoma in childhood after introduction of selective vaccination against hepatitis B virus for infants born to HBV carrier mothers. Cancer Causes Control: CCC. 2011;22(3):523–7. doi:10.1007/s10552-010-9721-4.CrossRefPubMed

10.

Bhadri VA, Stormon MO, Arbuckle S, Lam AH, Gaskin KJ, Shun A. Hepatocellular carcinoma in children with Alagille syndrome. J Pediatr Gastroenterol Nutr. 2005;41(5):676–8.CrossRefPubMed

11.

Labrune P, Trioche P, Duvaltier I, Chevalier P, Odievre M. Hepatocellular adenomas in glycogen storage disease type I and III: a series of 43 patients and review of the literature. J Pediatr Gastroenterol Nutr. 1997;24(3):276–9.CrossRefPubMed

12.

Katzenstein HM, London WB, Douglass EC, Reynolds M, Plaschkes J, Finegold MJ, et al. Treatment of unresectable and metastatic hepatoblastoma: a pediatric oncology group phase II study. J Clin Oncol. 2002;20(16):3438–44.CrossRefPubMed

13.

Brown J, Perilongo G, Shafford E, Keeling J, Pritchard J, Brock P, et al. Pretreatment prognostic factors for children with hepatoblastoma—results from the International Society of Paediatric Oncology (SIOP) study SIOPEL 1. Eur J Cancer. 2000;36(11):1418–25.CrossRefPubMed

14.

•• Zsiros J, Brugieres L, Brock P, Roebuck D, Maibach R, Zimmermann A, et al. Dose-dense cisplatin-based chemotherapy and surgery for children with high-risk hepatoblastoma (SIOPEL-4): a prospective, single-arm, feasibility study. Lancet Oncol. 2013;14(9):834–42. doi:10.1016/S1470-2045(13)70272-9. Report of successful treatment of patients with metastatic hepatoblastoma.CrossRefPubMedPubMedCentral

15.

Katzenstein HM, Krailo MD, Malogolowkin MH, Ortega JA, Liu-Mares W, Douglass EC, et al. Hepatocellular carcinoma in children and adolescents: results from the Pediatric Oncology Group and the Children’s Cancer Group intergroup study. J Clin Oncol. 2002;20(12):2789–97.CrossRefPubMed

16.

Czauderna P, Mackinlay G, Perilongo G, Brown J, Shafford E, Aronson D, et al. Hepatocellular carcinoma in children: results of the first prospective study of the International Society of Pediatric Oncology group. J Clin Oncol. 2002;20(12):2798–804. doi:10.1200/JCO.2002.06.102.CrossRefPubMed

17.

•• Lopez-Terrada D, Alaggio R, de Davila MT, Czauderna P, Hiyama E, Katzenstein H, et al. Towards an international pediatric liver tumor consensus classification: proceedings of the Los Angeles COG liver tumors symposium. Mod Pathol. 2014;27(3):472–91. doi:10.1038/modpathol.2013.80. Report of the first international consensus on pathologic classification of pediatric liver tumors.PubMed

18.

•• Sumazin P, Chen Y, Trevino LR, Sarabia SF, Hampton OA, Patel K, et al. Genomic analysis of hepatoblastoma identifies distinct molecular and prognostic subgroups. Hepatology. 2016. doi:10.1002/hep.28888. Report of the genomic analysis of hepatoblastoma on pretreatment tumor tissue.PubMed

19.

Prokurat A, Kluge P, Kosciesza A, Perek D, Kappeler A, Zimmermann A. Transitional liver cell tumors (TLCT) in older children and adolescents: a novel group of aggressive hepatic tumors expressing beta-catenin. Med Pediatr Oncol. 2002;39(5):510–8. doi:10.1002/mpo.10177.CrossRefPubMed

20.

Buendia MA. Unravelling the genetics of hepatoblastoma: few mutations, what else? J Hepatol. 2014;61(6):1202–4. doi:10.1016/j.jhep.2014.09.016.CrossRefPubMed

21.

• Xu L, Hazard FK, Zmoos AF, Jahchan N, Chaib H, Garfin PM, et al. Genomic analysis of fibrolamellar hepatocellular carcinoma. Hum Mol Genet. 2015;24(1):50–63. doi:10.1093/hmg/ddu418. Report of the advances in genomic analysis of hepatocellular carcinoma.CrossRefPubMed

22.

Kolbe AB, Podberesky DJ, Zhang B, Towbin AJ. The impact of hepatocyte phase imaging from infancy to young adulthood in patients with a known or suspected liver lesion. Pediatr Radiol. 2015;45(3):354–65. doi:10.1007/s00247-014-3160-4.CrossRefPubMed

23.

• Pugmire BS, Towbin AJ. Magnetic resonance imaging of primary pediatric liver tumors. Pediatr Radiol. 2016;46(6):764–77. doi:10.1007/s00247-016-3612-0. Report of the advances of imaging in pediatric liver tumors using MRI.CrossRefPubMed

24.

Roebuck DJ, Aronson D, Clapuyt P, Czauderna P, de Ville de Goyet J, Gauthier F, et al. 2005 PRETEXT: a revised staging system for primary malignant liver tumours of childhood developed by the SIOPEL group. Pediatr Radiol. 2007;37(2):123–32. doi:10.1007/s00247-006-0361-5. quiz 249–50.CrossRefPubMed

25.

Towbin AJ, Luo GG, Yin H, Mo JQ. Focal nodular hyperplasia in children, adolescents, and young adults. Pediatr Radiol. 2011;41(3):341–9. doi:10.1007/s00247-010-1839-8.CrossRefPubMed

26.

Smith EA, Salisbury S, Martin R, Towbin AJ. Incidence and etiology of new liver lesions in pediatric patients previously treated for malignancy. AJR Am J Roentgenol. 2012;199(1):186–91. doi:10.2214/AJR.11.7690.CrossRefPubMed

27.

Arcement CM, Towbin RB, Meza MP, Gerber DA, Kaye RD, Mazariegos GV, et al. Intrahepatic chemoembolization in unresectable pediatric liver malignancies. Pediatr Radiol. 2000;30(11):779–85. doi:10.1007/s002470000296.CrossRefPubMed

28.

Gerber DA, Arcement C, Carr B, Towbin R, Mazariegos G, Reyes J. Use of intrahepatic chemotherapy to treat advanced pediatric hepatic malignancies. J Pediatr Gastroenterol Nutr. 2000;30(2):137–44.CrossRefPubMed

29.

Brown DB, Cardella JF, Sacks D, Goldberg SN, Gervais DA, Rajan D, et al. Quality improvement guidelines for transhepatic arterial chemoembolization, embolization, and chemotherapeutic infusion for hepatic malignancy. J Vasc Interv Radiol. 2006;17(2 Pt 1):225–32. doi:10.1097/01.RVI.0000195330.47954.48.CrossRefPubMed

30.

McDaniel JD, Kukreja K, Ristagno RL, Yazigi N, Nathan JD, Tiao G. Radiofrequency ablation of a large hepatic adenoma in a child. J Pediatr Surg. 2013;48(6):E19–22. doi:10.1016/j.jpedsurg.2013.04.007.CrossRefPubMed

31.

Hawkins CM, Kukreja K, Geller JI, Schatzman C, Ristagno R. Radioembolisation for treatment of pediatric hepatocellular carcinoma. Pediatr Radiol. 2013;43(7):876–81. doi:10.1007/s00247-012-2568-y.CrossRefPubMed

32.

Colen RR, Hassan I, Elshafeey N, Zinn PO. Shedding light on the 2016 World Health Organization classification of tumors of the central nervous system in the era of radiomics and radiogenomics. Magn Reson Imaging Clin N Am. 2016;24(4):741–9. doi:10.1016/j.mric.2016.07.001.CrossRefPubMed

33.

•• Sala E, Mema E, Himoto Y, Veeraraghavan H, Brenton JD, Snyder A, et al. Unravelling tumour heterogeneity using next-generation imaging: radiomics, radiogenomics, and habitat imaging. Clin Radiol. 2016. doi:10.1016/j.crad.2016.09.013. Report on utilizing tumor heterogeneity on imaging to improve diagnosis of malignancies.PubMed

34.

Wiestler B, Kluge A, Lukas M, Gempt J, Ringel F, Schlegel J, et al. Multiparametric MRI-based differentiation of WHO grade II/III glioma and WHO grade IV glioblastoma. Sci Rep. 2016;6:35142. doi:10.1038/srep35142.CrossRefPubMedPubMedCentral

35.

Stoyanova R, Pollack A, Takhar M, Lynne C, Parra N, Lam LL, et al. Association of multiparametric MRI quantitative imaging features with prostate cancer gene expression in MRI-targeted prostate biopsies. Oncotarget. 2016;7(33):53362–76. doi:10.18632/oncotarget.10523.PubMedPubMedCentral

36.

Guo W, Li H, Zhu Y, Lan L, Yang S, Drukker K, et al. Prediction of clinical phenotypes in invasive breast carcinomas from the integration of radiomics and genomics data. J Med Imaging (Bellingham). 2015;2(4):041007. doi:10.1117/1.JMI.2.4.041007.CrossRef

37.

Czauderna P, Lopez-Terrada D, Hiyama E, Haberle B, Malogolowkin MH, Meyers RL. Hepatoblastoma state of the art: pathology, genetics, risk stratification, and chemotherapy. Curr Opin Pediatr. 2014;26(1):19–28. doi:10.1097/MOP.0000000000000046.CrossRefPubMed

38.

•• Czauderna P, Haeberle B, Hiyama E, Rangaswami A, Krailo M, Maibach R, et al. The Children’s Hepatic tumors International Collaboration (CHIC): novel global rare tumor database yields new prognostic factors in hepatoblastoma and becomes a research model. Eur J Cancer. 2016;52:92–101. doi:10.1016/j.ejca.2015.09.023. Report of the first international consensus of prognostic factors for hepatoblastoma following extensive review of the new international hepatoblastoma database.CrossRefPubMed

39.

•• Meyers RL, Maibach R, Hiyama E, Haberle B, Krailo M, Rangaswami A, et al. Risk-stratified staging in paediatric hepatoblastoma: a unified analysis from the Children’s Hepatic tumors International Collaboration. Lancet Oncol. 2016. doi:10.1016/S1470-2045(16)30598-8. Report of the first international consensus on risk stratification in hepatoblastoma following extensive review of the new international hepatoblastoma database.PubMedCentral

40.

Raney B. Hepatoblastoma in children: a review. J Pediatr Hematol Oncol. 1997;19(5):418–22.CrossRefPubMed

41.

Strasberg SM. Nomenclature of hepatic anatomy and resections: a review of the Brisbane 2000 system. J Hepatobiliary Pancreat Surg. 2005;12(5):351–5. doi:10.1007/s00534-005-0999-7.CrossRefPubMed

42.

Meyers RL, Tiao G, de Ville de Goyet J, Superina R, Aronson DC. Hepatoblastoma state of the art: pre-treatment extent of disease, surgical resection guidelines and the role of liver transplantation. Curr Opin Pediatr. 2014;26(1):29–36. doi:10.1097/MOP.0000000000000042.CrossRefPubMed

43.

Malogolowkin MH, Katzenstein HM, Meyers RL, Krailo MD, Rowland JM, Haas J, et al. Complete surgical resection is curative for children with hepatoblastoma with pure fetal histology: a report from the Children’s Oncology Group. J Clin Oncol. 2011. doi:10.1200/JCO.2010.29.3837.PubMedPubMedCentral

44.

Otte JB, Pritchard J, Aronson DC, Brown J, Czauderna P, Maibach R, et al. Liver transplantation for hepatoblastoma: results from the International Society of Pediatric Oncology (SIOP) study SIOPEL-1 and review of the world experience. Pediatr Blood Cancer. 2004;42(1):74–83. doi:10.1002/pbc.10376.CrossRefPubMed

45.

Otte JB, Meyers RL, de Ville de Goyet J. Transplantation for liver tumors in children: time to (re)set the guidelines? Pediatr Transplant. 2013;17(8):710–2. doi:10.1111/petr.12160.CrossRefPubMed

46.

Warmann SW, Schenk A, Schaefer JF, Ebinger M, Blumenstock G, Tsiflikas I, et al. Computer-assisted surgery planning in children with complex liver tumors identifies variability of the classical Couinaud classification. J Pediatr Surg. 2016;51(11):1801–6. doi:10.1016/j.jpedsurg.2016.05.018.CrossRefPubMed

47.

Ortega JA, Douglass EC, Feusner JH, Reynolds M, Quinn JJ, Finegold MJ, et al. Randomized comparison of cisplatin/vincristine/fluorouracil and cisplatin/continuous infusion doxorubicin for treatment of pediatric hepatoblastoma: a report from the Children’s Cancer Group and the Pediatric Oncology Group. J Clin Oncol. 2000;18(14):2665–75.PubMed

48.

Peterson RD, Varco RL, Good RA. A 5-year survival of an infant after surgical excision of an embryonal hepatoma. Pediatrics. 1961;27:474–6.PubMed

49.

Exelby PR, Filler RM, Grosfeld JL. Liver tumors in children in the particular reference to hepatoblastoma and hepatocellular carcinoma: American Academy of Pediatrics Surgical Section Survey—1974. J Pediatr Surg. 1975;10(3):329–37.CrossRefPubMed

50.

Evans AE, Land VJ, Newton WA, Randolph JG, Sather HN, Tefft M. Combination chemotherapy (vincristine, adriamycin, cyclophosphamide, and 5-fluorouracil) in the treatment of children with malignant hepatoma. Cancer. 1982;50(5):821–6.CrossRefPubMed

51.

Ortega JA, Krailo MD, Haas JE, King DR, Ablin AR, Quinn JJ, et al. Effective treatment of unresectable or metastatic hepatoblastoma with cisplatin and continuous infusion doxorubicin chemotherapy: a report from the Children’s Cancer Study Group. J Clin Oncol. 1991;9(12):2167–76.CrossRefPubMed

52.

Douglass EC, Reynolds M, Finegold M, Cantor AB, Glicksman A. Cisplatin, vincristine, and fluorouracil therapy for hepatoblastoma: a Pediatric Oncology Group study. J Clin Oncol. 1993;11(1):96–9.CrossRefPubMed

53.

von Schweinitz D, Byrd DJ, Hecker H, Weinel P, Bode U, Burger D, et al. Efficiency and toxicity of ifosfamide, cisplatin and doxorubicin in the treatment of childhood hepatoblastoma. Study Committee of the Cooperative Paediatric Liver Tumour Study HB89 of the German Society for Paediatric Oncology and Haematology. Eur J Cancer. 1997;33(8):1243–9.CrossRef

54.

Perilongo G, Shafford E, Maibach R, Aronson D, Brugieres L, Brock P, et al. Risk-adapted treatment for childhood hepatoblastoma. Final report of the second study of the International Society of Paediatric Oncology—SIOPEL 2. Eur J Cancer. 2004;40(3):411–21.CrossRefPubMed

55.

Malogolowkin MH, Katzenstein HM, Krailo M, Chen Z, Quinn JJ, Reynolds M, et al. Redefining the role of doxorubicin for the treatment of children with hepatoblastoma. J Clin Oncol. 2008;26(14):2379–83. doi:10.1200/JCO.2006.09.7204.CrossRefPubMedPubMedCentral

56.

Zsiros J, Maibach R, Shafford E, Brugieres L, Brock P, Czauderna P, et al. Successful treatment of childhood high-risk hepatoblastoma with dose-intensive multiagent chemotherapy and surgery: final results of the SIOPEL-3HR study. J Clin Oncol. 2010;28(15):2584–90. doi:10.1200/JCO.2009.22.4857.CrossRefPubMed

57.

Perilongo G, Maibach R, Shafford E, Brugieres L, Brock P, Morland B, et al. Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma. N Engl J Med. 2009;361(17):1662–70. doi:10.1056/NEJMoa0810613.CrossRefPubMed

58.

Trobaugh-Lotrario AD, Tomlinson GE, Finegold MJ, Gore L, Feusner JH. Small cell undifferentiated variant of hepatoblastoma: adverse clinical and molecular features similar to rhabdoid tumors. Pediatr Blood Cancer. 2009;52(3):328–34. doi:10.1002/pbc.21834.CrossRefPubMedPubMedCentral

59.

Yu SB, Kim HY, Eo H, Won JK, Jung SE, Park KW, et al. Clinical characteristics and prognosis of pediatric hepatocellular carcinoma. World J Surg. 2006;30(1):43–50. doi:10.1007/s00268-005-7965-z.CrossRefPubMed

60.

Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology. 2001;33(6):1394–403. doi:10.1053/jhep.2001.24563.CrossRefPubMed

61.

Gupta AA, Gerstle JT, Ng V, Wong A, Fecteau A, Malogolowkin MH, et al. Critical review of controversial issues in the management of advanced pediatric liver tumors. Pediatr Blood Cancer. 2011;56(7):1013–8. doi:10.1002/pbc.22893.CrossRefPubMed

62.

Ismail H, Broniszczak D, Kalicinski P, Dembowska-Baginska B, Perek D, Teisseyre J, et al. Changing treatment and outcome of children with hepatoblastoma: analysis of a single center experience over the last 20 years. J Pediatr Surg. 2012;47(7):1331–9. doi:10.1016/j.jpedsurg.2011.11.073.CrossRefPubMed

63.

Beaunoyer M, Vanatta JM, Ogihara M, Strichartz D, Dahl G, Berquist WE, et al. Outcomes of transplantation in children with primary hepatic malignancy. Pediatr Transplant. 2007;11(6):655–60. doi:10.1111/j.1399-3046.2007.00751.x.CrossRefPubMed

64.

Murawski M, Weeda VB, Maibach R, Morland B, Roebuck DJ, Zimmerman A, et al. Hepatocellular carcinoma in children: does modified platinum- and doxorubicin-based chemotherapy increase tumor resectability and change outcome? Lessons learned from the SIOPEL 2 and 3 studies. J Clin Oncol. 2016;34(10):1050–6. doi:10.1200/JCO.2014.60.2250.CrossRefPubMed

65.

Schmid I, Haberle B, Albert MH, Corbacioglu S, Frohlich B, Graf N, et al. Sorafenib and cisplatin/doxorubicin (PLADO) in pediatric hepatocellular carcinoma. Pediatr Blood Cancer. 2012;58(4):539–44. doi:10.1002/pbc.23295.CrossRefPubMed

66.

O’Neill AF, Hanto DW, Katzenstein HM. Cause and effect: the etiology of pediatric hepatocellular carcinoma and the role for liver transplantation. Pediatr Transplant. 2016;20(7):878–9. doi:10.1111/petr.12781.CrossRefPubMed

67.

Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–90. doi:10.1056/NEJMoa0708857.CrossRefPubMed

68.

Honeyman JN, Simon EP, Robine N, Chiaroni-Clarke R, Darcy DG, Lim II, et al. Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma. Science. 2014;343(6174):1010–4. doi:10.1126/science.1249484.CrossRefPubMedPubMedCentral

69.

Yaghmour G, Pandey M, Ireland C, Patel K, Nunnery S, Powell D, et al. Role of genomic instability in immunotherapy with checkpoint inhibitors. Anticancer Res. 2016;36(8):4033–8.PubMed

70.

El-Khoueiry AB MI, Crocenzi TS, et al. Phase I/II safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma (HCC). J Clin Oncol 33. 2015(Ca209-040):suppl; abstr LBA101.

71.

Hoffer FA. Interventional oncology: the future. Pediatr Radiol. 2011;41 Suppl 1:S201–6. doi:10.1007/s00247-011-1990-x.CrossRefPubMed

72.

Graziadei IW, Sandmueller H, Waldenberger P, Koenigsrainer A, Nachbaur K, Jaschke W, et al. Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome. Liver Transpl. 2003;9(6):557–63. doi:10.1053/jlts.2003.50106.CrossRefPubMed

73.

Morimoto M, Numata K, Kondou M, Nozaki A, Morita S, Tanaka K. Midterm outcomes in patients with intermediate-sized hepatocellular carcinoma: a randomized controlled trial for determining the efficacy of radiofrequency ablation combined with transcatheter arterial chemoembolization. Cancer. 2010;116(23):5452–60. doi:10.1002/cncr.25314.CrossRefPubMed

74.

Zhang J, Xu F, Chen K, Zhou S, Li H, Niu C, et al. An effective approach for treating unresectable hepatoblastoma in infants and children: pre-operative transcatheter arterial chemoembolization. Oncol Lett. 2013;6(3):850–4. doi:10.3892/ol.2013.1444.PubMedPubMedCentral

Title: Advances in Pediatric Liver Tumors
Authors: Angela D. Trobaugh-Lotrario
Allison F. O’Neill
Peng Li
Alexander Towbin
Christopher Weldon
Dolores López-Terrada
Marcio H. Malogolowkin
Publication date: 01-03-2017
Publisher: Springer US
Published in: Current Hepatology Reports / Issue 1/2017
Electronic ISSN: 2195-9595
DOI: https://doi.org/10.1007/s11901-017-0335-0

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 1/2017

Tailored Algorithms for Hepatocellular Carcinoma Surveillance: Is One-Size-Fits-All Strategy Outdated?

Future Paradigms of HCV Management with Resistance Testing

Understanding LI-RADS, Its Relationship to AASLD and OPTN, and the Challenges of Its Adoption

Use of Hepatitis C-Positive Donor Livers in Liver Transplantation

Racial/Ethnic Disparities in Hepatocellular Carcinoma Epidemiology

Changes in Liver Transplant Criteria for Hepatocellular Carcinoma

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage